Palette Life Sciences Revenue and Competitors

Palette Life Sciences is a fully-integrated medical device company focused on providing a wide range of products and services that improve the quality of life for patients. Led by experienced healthcare executives, the initial company strategy is to transform applications of existing technologies to bring forward novel solutions for underserved conditions. Our portfolio of products focuses on treating conditions in urology/urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. We are a passionate team of individuals who enjoy the thrill of building a company whose culture is one of curiosity, compassion and drive. Looking for like-minded staff that has a complementary experience to add to the team. Our superior benefits package is proof positive that we care about our people. Deflux® - the only FDA-approved injectable treatment of vesicoureteral reflux (VUR), a malformation of the urinary bladder that affects 1% of children worldwide. VUR can cause severe infections of the urinary tract and lead to irreversible kidney damage. Solesta® - the only FDA-approved injectable treatment for fecal incontinence, which is also cleared for commercialization in Europe. Fecal incontinence is a debilitating health problem afflicting about 2% of people worldwide with four times more prevalent in women than men. Barrigel®* - a biodegradable injectable treatment for protection of the rectal wall when treating prostate cancer with radiation. The product is approved in Europe and will be further developed for future market introduction in the US. Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California and Dallas, Texas. Learn more at palettelifesciences.com and pharmanest.se. Deflux®, Solesta®, Barrigel®, Restylane®, and NASHA™ are registered trademarks. *In the US, this product is considered investigational and not available for commercial sale in the US.